Cancer Advisor

Joe Tippens never planned to discover a potential remedy that he credits with saving his life and thrust him into the spotlight among notable cancer survivors. The 67-year-old businessman told The Epoch Times he just wanted to beat a type of cancer with an extremely low survival rate. In August 2016, Tippens was diagnosed with small cell lung cancer with a fist-sized tumor. After undergoing chemotherapy and radiation five times a week in Houston, the large tumor in his left lung was eliminated. However, Tippens said the treatments came closer to killing him than curing him. When he returned home to Oklahoma after the New Year, he received devastating news. His oncologist told him he had zero chance of surviving for more than a few months. “In January of 2017, my PET scan lit up like a Christmas tree and I had wide metastasis everywhere, including in my neck, bones, pancreas, and liver,” Tippens said. Finding a Lifeline Facing a prognosis of three months to live, Tippens heard an intrig...

Abstract Background: Precision oncology has traditionally relied on population-based evidence, yet tumor heterogeneity and dynamic resistance limit durable responses. N=1 adaptive strategies—where treatment is continuously tailored to an individual patient—represent a promising paradigm shift. Methods: We developed an in silico prospective cohort of 10 virtual patients with advanced KRAS-mutant non-small cell lung cancer (NSCLC). Each patient underwent iterative treatment guided by simulated circulating tumor DNA (ctDNA), imaging, and evolving tumor genomics. The adaptive cohort was compared against a simulated standard-of-care (SOC) arm consisting of chemotherapy ± Pembrolizumab. Primary endpoint was progression-free survival (PFS). Results: Median PFS improved from 7.8 months (SOC) to 17.6 months (adaptive N=1 strategy). Early ctDNA-guided intervention enabled detection of resistance approximately 8–10 weeks prior to radiographic progression, consistent with prior clinical observa...

In a revealing post on X (formerly Twitter), whistleblower account @Jikkyleaks has shed light on four prominent universities that have quietly pursued patents and research on anti-parasitic medications—such as ivermectin, mebendazole, and fenbendazole—for treating various cancers. These drugs, long used to combat parasites in humans and animals, are now being explored for their potential anticancer properties.  The post, which credits AI assistant Grok for verifying the details, questions why this potentially game-changing information hasn't been more publicly disseminated. Drawing from the post and its sources, this article explores the universities involved, the science behind the drugs, and the broader implications. The Universities and Their Patent Pursuits According to the information compiled in the post, these institutions have been actively involved in patenting or researching these repurposed drugs. Here's a breakdown: University of British Columbia (UBC) The Universi...